Switch theme
Sign up to access all valuation multiples
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
2015
n/a
LTM Revenue n/a
LTM EBITDA n/a
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chongqing Genrix has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chongqing Genrix achieved revenue of $0.2M and an EBITDA of -$97.4M.
Chongqing Genrix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chongqing Genrix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | n/a | XXX | XXX | XXX |
| Gross Profit | $2.7M | -$7K | XXX | XXX | XXX |
| Gross Margin | 1633% | NaN% | XXX | XXX | XXX |
| EBITDA | -$97.4M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -58371% | NaN% | XXX | XXX | XXX |
| Net Profit | -$44.4M | -$79.4M | XXX | XXX | XXX |
| Net Margin | -26590% | NaN% | XXX | XXX | XXX |
| Net Debt | $71.8M | $95.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Chongqing Genrix's stock price is CNY 32 (or $4).
Chongqing Genrix has current market cap of CNY 11.8B (or $1.6B), and EV of CNY 10.0B (or $1.4B).
See Chongqing Genrix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.6B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Chongqing Genrix has market cap of $1.6B and EV of $1.4B.
Chongqing Genrix's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Chongqing Genrix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Chongqing Genrix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChongqing Genrix's NTM/LTM revenue growth is n/a
Chongqing Genrix's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Chongqing Genrix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Chongqing Genrix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Chongqing Genrix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 105% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10436% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 51209% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 64966% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chongqing Genrix acquired XXX companies to date.
Last acquisition by Chongqing Genrix was XXXXXXXX, XXXXX XXXXX XXXXXX . Chongqing Genrix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Chongqing Genrix founded? | Chongqing Genrix was founded in 2015. |
| Where is Chongqing Genrix headquartered? | Chongqing Genrix is headquartered in China. |
| Is Chongqing Genrix publicy listed? | Yes, Chongqing Genrix is a public company listed on SHG. |
| What is the stock symbol of Chongqing Genrix? | Chongqing Genrix trades under 688443 ticker. |
| When did Chongqing Genrix go public? | Chongqing Genrix went public in 2023. |
| Who are competitors of Chongqing Genrix? | Similar companies to Chongqing Genrix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Chongqing Genrix? | Chongqing Genrix's current market cap is $1.6B |
| Is Chongqing Genrix profitable? | Yes, Chongqing Genrix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
